• Optimizing ART With Novel HIV Agents

  • Aug 16 2024
  • Length: 13 mins
  • Podcast

Optimizing ART With Novel HIV Agents

Listen for free

View show details

  • Summary

  • In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

    Listen as he discusses:

    • The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
    • Options in people with multiclass resistance
    • Studies of agents with novel mechanisms of action:
      • BRIGHTE (fostemsavir)
      • TMB-301/-311 (ibalizumab)
      • CAPELLA (lenacapavir)

    Faculty

    ​​Gregory Huhn, MD, MPHTM,
    Interim Chief, Division of Infectious Diseases
    Senior Director of HIV Services
    Cook County HIV Integrated Programs
    Interim Medical Director, The RMR CORE Center
    Professor, Division of Infectious Diseases
    Rush University Medical Center
    Chicago, Illinois

    Follow along with the slides.
    https://bit.ly/4fHmxg5

    Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.

    Show more Show less
Show more Show less

What listeners say about Optimizing ART With Novel HIV Agents

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available